Table 1 Characteristics of the study populations.

From: Free-breathing cardiovascular magnetic resonance flow quantification can be an alternative to standard breath-holding approach

 

Healthy subjects (n = 20)

Tricuspid regurgitation (n = 25)

Age (years)

31 ± 7

54 ± 14

Female, n (%)

9 (45%)

15 (60%)

Body surface area (m2)

1.80 ± 0.19

1.89 ± 0.22

Heart rate (beats/min)

63 ± 11

75 ± 13

SBP (mm Hg)

120 ± 7

135 ± 22

DBP (mm Hg)

75 ± 5

77 ± 11

Tricuspid annular dilation n (%)

-

8 (32%)

Tenting / tethering n (%)

-

6 (24%)

Tricuspid valve prolapse, n (%)

-

6 (26%)

Pulmonary hypertension

-

8 (32%)

History of heart transplantation

-

5 (20%)

History of endocarditis, n (%)

-

3 (12%)

History of chest radiation therapy

-

3 (12%)

Symptoms, n (%)

-

14 (56%)

Cardiovascular risk factors, n (%)

  

Coronary artery disease

-

3 (12%)

Hypertension

-

7 (28%)

Hyperlipidemia

-

1 (4%)

Diabetes mellitus

-

1 (4%)

Enlarged right ventricle, n (%)

-

9 (36%)

CMR TR RVol ≥ 45 ml

-

9 (36%)

  1. Tricuspid annular dilation defined as annular diameter > 21 mm/m2 in apical 4 chamber view. RVol, regurgitant volume = right ventricular stroke volume (RVSV) - pulmonary forward flow volume (PuFF).